Replies to post #171589 on Biotech Values

[DewDiligence]

A more fundamental problem with looking for an analog, which I think Dew has spoken to before, is that we're talking about, in the scheme of things, a very short treatment duration, while compliance is usually thought of more on terms of chronic diseases. So while compliance might logically be worse for ABBV/ENTA, I don't know how important this will be to prescribers or payers, especially given how hard it would be to actually prove a difference in compliance between regimens.

Amen. The pill burden argument against ABBV/ENTA is one of the foremost canards floating around in biotechland these days.